Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biophytis ( (BPTSY) ) just unveiled an update.
On June 30, 2025, Biophytis SA announced that it was unable to publish its 2024 annual accounts on the previously scheduled date. The company aims to release these accounts by July 7, 2025. This delay may impact stakeholders’ perception of the company’s financial transparency and could influence its market positioning.
The most recent analyst rating on (BPTSY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Their lead drug candidate, BIO101, is being developed for muscular diseases like sarcopenia and metabolic disorders such as obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis’ shares are listed on Euronext Growth Paris and its ADS on the OTC market.
Average Trading Volume: 25
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.42M
For an in-depth examination of BPTSY stock, go to TipRanks’ Overview page.